FDA Publishes Guidance on Clinical Trials
At the beginning of August, the FDA released a guideline on monitoring of clinical trials. This document is the final version of a draft dated August 2011 in which a few comments have been integrated. The guideline includes for example more details about the performance of risk-based monitoring and monitoring technique. The document entitled "Guidance for Industry Oversight of Clinical Investigations - A Risk-Based Approach to Monitoring" has a pretty wide scope and applies to both medicinal products and medical devices. With this guideline, the FDA aims to support the sponsors of clinical trials with medicinal products (chemical and biological APIs), and/ or with medical devices (Investigational Devices Exemption (IDE) studies) and/ or combination products. Patient safety is, of course, the main concern. The quality of data is also addressed. To ensure it, the sponsor has to focus - with his/ her monitoring activities - on the main aspects of the studies and the related reports. In a word, he/ she has to choose a risk-based approach. The 22-page guideline tries to describe these two main objectives.
The guideline can be found here.
Related GMP News
21.01.2025FDA Warning Letter Statistics on Medical Devices in the past Fiscal Year
21.01.2025Artificial Intelligence in Medical Devices - Notified Bodies' Point of View
21.01.2025New FDA Guidance on Risk Analyses for Drugs, Biologics and Combination Products
08.10.2024EMA updates Question and Answer Document on Combination Products
08.10.2024Transparency Guidelines for Medical Devices with Artificial Intelligence
12.09.2024Notified Body Survey on Certificates & Applications under the Medical Devices/IVD Regulation